ArticleInternational journal of hematology2021

Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.

Dmitry Evseev et al.PubMed ↗Publisher ↗

No numbers read from the abstract.